Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 319

1.

Synergistic meropenem-tobramycin combination dosage regimens against clinical hypermutable Pseudomonas aeruginosa at simulated epithelial lining fluid concentrations in a dynamic biofilm model.

Bilal H, Bergen PJ, Kim TH, Chung SE, Peleg AY, Oliver A, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.01293-19. doi: 10.1128/AAC.01293-19. [Epub ahead of print]

PMID:
31427301
2.

Conclusion.

Nation RL.

Adv Exp Med Biol. 2019;1145:363-364. doi: 10.1007/978-3-030-16373-0_21.

PMID:
31364087
3.

Mechanisms of Polymyxin-Induced Nephrotoxicity.

Azad MAK, Nation RL, Velkov T, Li J.

Adv Exp Med Biol. 2019;1145:305-319. doi: 10.1007/978-3-030-16373-0_18.

PMID:
31364084
4.

Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic Use.

Nation RL, Forrest A.

Adv Exp Med Biol. 2019;1145:219-249. doi: 10.1007/978-3-030-16373-0_15.

PMID:
31364081
5.

Labelling Conventions and Product Package Insert of Parenteral Polymyxins: Factors Causing Potential Medication Errors and Impeding Optimal Clinical Use.

Li J, Coulthard K, Nation RL.

Adv Exp Med Biol. 2019;1145:133-141. doi: 10.1007/978-3-030-16373-0_10.

PMID:
31364076
6.

Optimization of dosing regimens of intravenous colistin in patients with cystic fibrosis: What data are required?

Nation RL, Landersdorfer CB.

Pediatr Pulmonol. 2019 Jul 8. doi: 10.1002/ppul.24444. [Epub ahead of print] No abstract available.

PMID:
31286687
7.

Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity.

Nation RL, Rigatto MHP, Falci DR, Zavascki AP.

Antibiotics (Basel). 2019 Mar 14;8(1). pii: E24. doi: 10.3390/antibiotics8010024. Review.

8.

Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Rees VE, Deveson Lucas DS, López-Causapé C, Huang Y, Kotsimbos T, Bulitta JB, Rees MC, Barugahare A, Peleg AY, Nation RL, Oliver A, Boyce JD, Landersdorfer CB.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02538-18. doi: 10.1128/AAC.02538-18. Print 2019 Apr.

PMID:
30745381
9.

Population pharmacokinetics of intravenous colistin in pediatric patients: Implications for selection of dosage regimens.

Ooi MH, Ngu SJ, Chor YK, Li J, Landersdorfer CB, Nation RL.

Clin Infect Dis. 2019 Jan 26. doi: 10.1093/cid/ciz067. [Epub ahead of print]

PMID:
30722017
10.
11.

Norbornane-based cationic antimicrobial peptidomimetics targeting the bacterial membrane.

Hickey SM, Ashton TD, Boer G, Bader CA, Thomas M, Elliott AG, Schmuck C, Yu HY, Li J, Nation RL, Cooper MA, Plush SE, Brooks DA, Pfeffer FM.

Eur J Med Chem. 2018 Dec 5;160:9-22. doi: 10.1016/j.ejmech.2018.09.072. Epub 2018 Oct 3.

PMID:
30316060
12.
13.

Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.

Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01150-18. doi: 10.1128/AAC.01150-18. Print 2018 Nov.

14.

Concentration-dependent plasma protein binding: Expect the unexpected.

Nation RL, Theuretzbacher U, Tsuji BT; International Society of Anti-Infective Pharmacology (ISAP).

Eur J Pharm Sci. 2018 Sep 15;122:341-346. doi: 10.1016/j.ejps.2018.07.004. Epub 2018 Jul 3. Review.

PMID:
30026170
15.

Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.

Lakota EA, Landersdorfer CB, Nation RL, Li J, Kaye KS, Rao GG, Forrest A.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00483-18. doi: 10.1128/AAC.00483-18. Print 2018 Jul.

16.

Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.

Bulman ZP, Zhao M, Satlin MJ, Chen L, Kreiswirth BN, Walsh TJ, Nation RL, Li J, Tsuji BT.

Int J Antimicrob Agents. 2018 Jul;52(1):114-118. doi: 10.1016/j.ijantimicag.2018.02.010. Epub 2018 Feb 24.

PMID:
29486233
17.

Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Yadav R, Rogers KE, Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00078-18. doi: 10.1128/AAC.00078-18. Print 2018 May.

18.

Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.

Landersdorfer CB, Rees VE, Yadav R, Rogers KE, Kim TH, Bergen PJ, Cheah SE, Boyce JD, Peleg AY, Oliver A, Shin BS, Nation RL, Bulitta JB.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02055-17. doi: 10.1128/AAC.02055-17. Print 2018 Apr.

19.

Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria.

Velkov T, Gallardo-Godoy A, Swarbrick JD, Blaskovich MAT, Elliott AG, Han M, Thompson PE, Roberts KD, Huang JX, Becker B, Butler MS, Lash LH, Henriques ST, Nation RL, Sivanesan S, Sani MA, Separovic F, Mertens H, Bulach D, Seemann T, Owen J, Li J, Cooper MA.

Cell Chem Biol. 2018 Apr 19;25(4):380-391.e5. doi: 10.1016/j.chembiol.2018.01.005. Epub 2018 Feb 3.

20.

Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.

Landersdorfer CB, Yadav R, Rogers KE, Kim TH, Shin BS, Boyce JD, Nation RL, Bulitta JB.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02053-17. doi: 10.1128/AAC.02053-17. Print 2018 Apr.

21.

Assessment and modelling of antibacterial combination regimens.

Rao GG, Li J, Garonzik SM, Nation RL, Forrest A.

Clin Microbiol Infect. 2018 Jul;24(7):689-696. doi: 10.1016/j.cmi.2017.12.004. Epub 2017 Dec 18. Review.

22.

Dose Suggestions for Intravenous Colistin in Pediatric Patients: Caution Required.

Nation RL.

Clin Infect Dis. 2018 Feb 10;66(5):810-811. doi: 10.1093/cid/cix1048. No abstract available.

PMID:
29211826
23.

Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models.

Landersdorfer CB, Wang J, Wirth V, Chen K, Kaye KS, Tsuji BT, Li J, Nation RL.

J Antimicrob Chemother. 2018 Feb 1;73(2):462-468. doi: 10.1093/jac/dkx409.

24.

Design and Evaluation of Novel Polymyxin Fluorescent Probes.

Yun B, Roberts KD, Thompson PE, Nation RL, Velkov T, Li J.

Sensors (Basel). 2017 Nov 11;17(11). pii: E2598. doi: 10.3390/s17112598.

25.

Methionine Ameliorates Polymyxin-Induced Nephrotoxicity by Attenuating Cellular Oxidative Stress.

Azad MAK, Sivanesan S, Wang J, Chen K, Nation RL, Thompson PE, Roberts KD, Velkov T, Li J.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01254-17. doi: 10.1128/AAC.01254-17. Print 2018 Jan.

26.

Reply to Corona and Cattaneo.

Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A, Paterson DL, Li J, Silveira FP.

Clin Infect Dis. 2017 Sep 1;65(5):870-871. doi: 10.1093/cid/cix390. No abstract available.

27.

Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.

Yadav R, Bulitta JB, Wang J, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01268-17. doi: 10.1128/AAC.01268-17. Print 2017 Dec.

28.

Gelofusine Ameliorates Colistin-Induced Nephrotoxicity.

Sivanesan SS, Azad MAK, Schneider EK, Ahmed MU, Huang J, Wang J, Li J, Nation RL, Velkov T.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00985-17. doi: 10.1128/AAC.00985-17. Print 2017 Dec.

29.

Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.

Yadav R, Bulitta JB, Schneider EK, Shin BS, Velkov T, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00722-17. doi: 10.1128/AAC.00722-17. Print 2017 Dec.

30.

Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients.

Forrest A, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, Li J, Silveira FP, Nation RL.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01367-17. doi: 10.1128/AAC.01367-17. Print 2017 Nov.

31.

The first total synthesis and solution structure of a polypeptin, PE2, a cyclic lipopeptide with broad spectrum antibiotic activity.

Mountford SJ, Mohanty B, Roberts KD, Yu HH, Scanlon MJ, Nation RL, Velkov T, Li J, Thompson PE.

Org Biomol Chem. 2017 Aug 30;15(34):7173-7180. doi: 10.1039/c7ob01493g.

PMID:
28812779
32.

Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era.

Bulman ZP, Chen L, Walsh TJ, Satlin MJ, Qian Y, Bulitta JB, Peloquin CA, Holden PN, Nation RL, Li J, Kreiswirth BN, Tsuji BT.

MBio. 2017 Jul 25;8(4). pii: e00540-17. doi: 10.1128/mBio.00540-17.

33.

Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.

Smith NM, Bulman ZP, Sieron AO, Bulitta JB, Holden PN, Nation RL, Li J, Wright GD, Tsuji BT.

J Antimicrob Chemother. 2017 Aug 1;72(8):2297-2303. doi: 10.1093/jac/dkx121.

34.

Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.

Zhao M, Bulman ZP, Lenhard JR, Satlin MJ, Kreiswirth BN, Walsh TJ, Marrocco A, Bergen PJ, Nation RL, Li J, Zhang J, Tsuji BT.

J Antimicrob Chemother. 2017 Jul 1;72(7):1985-1990. doi: 10.1093/jac/dkx070.

35.

Critical Need for Clarity in Polymyxin B Dosing.

Onufrak NJ, Rao GG, Forrest A, Pogue JM, Scheetz MH, Nation RL, Li J, Kaye KS.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e00208-17. doi: 10.1128/AAC.00208-17. Print 2017 May. No abstract available.

36.

Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii.

Maifiah MH, Creek DJ, Nation RL, Forrest A, Tsuji BT, Velkov T, Li J.

Sci Rep. 2017 Mar 30;7:45527. doi: 10.1038/srep45527.

37.

Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.

Lenhard JR, Thamlikitkul V, Silveira FP, Garonzik SM, Tao X, Forrest A, Soo Shin B, Kaye KS, Bulitta JB, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2017 May 1;72(5):1415-1420. doi: 10.1093/jac/dkx002.

38.

Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02642-16. doi: 10.1128/AAC.02642-16. Print 2017 May.

39.

New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.

Bulman ZP, Satlin MJ, Chen L, Kreiswirth BN, Shin BS, Walsh TJ, Holden PN, Forrest A, Nation RL, Li J, Tsuji BT.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02023-16. doi: 10.1128/AAC.02023-16. Print 2017 Apr.

40.

Pharmacokinetics of the Individual Major Components of Polymyxin B and Colistin in Rats.

Sivanesan S, Roberts K, Wang J, Chea SE, Thompson PE, Li J, Nation RL, Velkov T.

J Nat Prod. 2017 Jan 27;80(1):225-229. doi: 10.1021/acs.jnatprod.6b01176. Epub 2017 Jan 12.

PMID:
28080060
41.

High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.

Lenhard JR, Smith NM, Bulman ZP, Tao X, Thamlikitkul V, Shin BS, Nation RL, Li J, Bulitta JB, Tsuji BT.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01268-16. doi: 10.1128/AAC.01268-16. Print 2017 Mar.

42.

Dosing guidance for intravenous colistin in critically-ill patients.

Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A, Paterson DL, Li J, Silveira FP.

Clin Infect Dis. 2017 Mar 1;64(5):565-571. doi: 10.1093/cid/ciw839. Epub 2016 Dec 23.

43.

Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?

Zavascki AP, Nation RL.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02319-16. doi: 10.1128/AAC.02319-16. Print 2017 Mar. Review.

44.

Low doses of colistimethate: Don't rush in!

Zavascki AP, Nation RL.

Clin Infect Dis. 2017 Mar 1;64(5):695-696. Epub 2016 Dec 16. No abstract available.

PMID:
27986687
45.

Synergistic combinations of polymyxins.

Lenhard JR, Nation RL, Tsuji BT.

Int J Antimicrob Agents. 2016 Dec;48(6):607-613. doi: 10.1016/j.ijantimicag.2016.09.014. Epub 2016 Oct 24. Review.

46.

Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.

Yadav R, Bulitta JB, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01011-16. doi: 10.1128/AAC.01011-16. Print 2017 Jan.

47.

Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.

Landersdorfer CB, Nguyen TH, Lieu LT, Nguyen G, Bischof RJ, Meeusen EN, Li J, Nation RL, McIntosh MP.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01934-16. doi: 10.1128/AAC.01934-16. Print 2017 Jan.

48.

Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, Li J.

Int J Antimicrob Agents. 2016 Dec;48(6):592-597. doi: 10.1016/j.ijantimicag.2016.09.010. Epub 2016 Oct 18. Review.

49.

Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Lenhard JR, Gall JS, Bulitta JB, Thamlikitkul V, Landersdorfer CB, Forrest A, Nation RL, Li J, Tsuji BT.

Int J Antimicrob Agents. 2016 Dec;48(6):719-724. doi: 10.1016/j.ijantimicag.2016.07.024. Epub 2016 Sep 20.

50.

High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah SE, Thamlikitkul V, Shin BS, Rao G, Holden PN, Walsh TJ, Forrest A, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2017 Jan;72(1):153-165. Epub 2016 Sep 15.

Supplemental Content

Loading ...
Support Center